Progress in Cardiovascular Diseases
Volume 53, Issue 2 , Pages 173-179 , September 2010

Developing a Cardiology-Oncology Clinical Practice Guideline

  • JoAnn Lindenfeld

      Affiliations

    • Corresponding Author InformationAddress reprint requests to JoAnn Lindenfeld, MD, University of Colorado Health Sciences Center, F749, Room 7083, Aurora, CO 80045.
    • ,
  • Patricia A. Kelly

References 

  1. Woolf SH, Grol R, Hutchinson A, et al. Clinical guidelines: potential benefits, limitations, and harms of clinical guidelines. BMJ. 1999;318:527–530
  2. Audet AM, Greenfield S, Field M. Medical practice guidelines: current activities and future directions. Ann Intern Med. 1990;113:709–714
  3. Poolman RW, Verheyen CC, Kerkhoffs GM, et al. From evidence to action: understanding clinical practice guidelines. Acta Orthop. 2009;80:113–118
  4. Guyatt GH, Oxman AD, Kunz R, et al. What is “quality of evidence” and why is it important to clinicians?. BMJ. 2008;336:995–998
  5. Oxman AD, Schünemann HJ, Fretheim A. Improving the use of research evidence in guideline development: 14. Reporting guidelines. Health Res Policy Syst. 2006;4:26–33
  6. National Guidelines Clearinghouse. Available from: http://www.guideline.gov/. Last accessed March 31, 2010.
  7. Guidelines International Network. Available from: http://www.g-i-n.net/. Last accessed July 26, 2010.
  8. McMurray J, Swedberg K. Treatment of chronic heart failure: a comparison between the major guidelines. Eur Heart J. 2006;27:1773–1777
  9. Heart Failure Society of America , Lindenfeld J, Albert NM, et al. HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Cardiac Failure. 2010;16:e1–e194
  10. Hunt SA, Abraham WT, Chin MH, et al. 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. J Am Coll Cardiol. 2009;53:e1–e90
  11. Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis,diagnosis, and management. J Am Coll Cardiol. 2009;53:2231–2247
  12. Heidenreich PA, Kapoor JR. Radiation induced heart disease: systemic disorders in heart disease. Heart. 2009;95:252–258
  13. Chu TF, Rupnick MA, Kerkela R, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet. 2007;370:2011–2019
  14. Anderson B, Sawyer DB. Predicting and preventing the cardiotoxicity of cancer therapy. Expert Rev Cardiovasc Ther. 2008;6:1023–1033
  15. Mulrooney DA, Yeazel MW, Kawashima T, et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ. 2009;b4606:339
  16. Maitland ML, Bakris GL, Black HR, et al. Cardiovascular Toxicities Panel, Convened by the Angiogenesis Task Force of the National Cancer Institute Investigational Drug Steering Committee. Initial Assessment, Surveillance, and Management of Blood Pressure in Patients Receiving Vascular Endothelial Growth Factor Signaling Pathway Inhibitors. J Natl Cancer Inst. 2010;102:596–604
  17. Yancik R, Ries LA. Cancer in older persons: an international issue in an aging world. Semin Oncol. 2004;21:128–136
  18. Yancik R, Wesley MN, Ries LA, et al. Comorbidity and age as predictors of risk for early mortality of male and female colon carcinoma patients: a population-based study. Cancer. 1998;82:2123–2134
  19. Yancik R, Wesley MN, Ries LA, et al. Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA. 2001;285:885–892
  20. American Heart Association. Available from: www.americanheart.org/statistics. Last accessed April 2, 2010.
  21. Pinder MC, Duan Z, Goodwin JS, et al. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol. 2007;25:3808–3815
  22. Lenihan DJ, Esteva FJ. Multidisciplinary strategy for managing cardiovascular risks when treating patients with early breast cancer. Oncologist. 2008;13:1224–1234
  23. Levy D, Kenchaiah S, Larson MG, et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med. 2002;347:1397–1402
  24. Roger VL, Weston SA, Redfield MM, et al. Trends in heart failure incidence and survival in a community-based population. JAMA. 2004;292:344–350
  25. Stewart S, MacIntyre K, Hole DJ, et al. More 'malignant' than cancer? Five-year survival following a first admission for heart failure. Eur J Heart Fail. 2001;3:315–322
  26. Askoxylakis V, Thieke C, Pleger ST, et al. Long-term survival of cancer patients compared to heart failure and stroke: a systematic review. BMC Cancer. 2010;10:105
  27. Boyd CM, Darer J, Boult C, et al. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. JAMA. 2005;294:716–724
  28. Parekh AK, Barton MB. The challenge of multiple comorbidity for the US health care system. JAMA. 2010;303:1303–1304
  29. Ewer MS, Lenihan DJ, Khakoo AY. Sunitinib-related cardiotoxicity: an interdisciplinary issue. Nat Clin Pract Cardiovasc Med. 2008;5:364–365
  30. Albini A, Pennesi G, Donatelli F, et al. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst. 2010;102:14–25
  31. Shephard RJ. Age and physical work capacity. Exp Aging Res. 1999;25:331–343
  32. Verbrugge LM, Patrick DL. Seven chronic conditions: their impact on US adults' activity levels and use of medical services. Am J Public Health. 1995;85:173–182
  33. Luciani A, Jacobsen PB, Extermann M, et al. Fatigue and functional dependence in older cancer patients. Am J Clin Oncol. 2008;31:424–430
  34. Masoudi FA, Baillie CA, Wang Y, et al. The complexity and cost of drug regimens of older patients hospitalized with HF in the United States, 1998-2001. Arch Intern Med. 2005;165:2069–2076
  35. Tam-McDevitt J. Polypharmacy, aging, and cancer. Oncology (Williston Park). 2008;22:1052–1055[discussion 1055, 1058, 1060]
  36. Flesch M, Erdmann E. The problem of polypharmacy in HF. Curr Cardiol Rep. 2006;8:217–225
  37. Vogels RL, Scheltens P, Schroeder-Tanka JM, et al. Cognitive impairment in HF: a systematic review of the literature. Eur J Heart Fail. 2007;9:440–449
  38. Zuccalà G, Cattel C, Manes-Gravina E, et al. Left ventricular dysfunction: a clue to cognitive impairment in older patients with HF. J Neurol Neurosurg Psychiatry. 1997;63:509–512
  39. Hermelink K, Küchenhoff H, Untch M, et al. Two different sides of ‘chemobrain’: determinants and nondeterminants of self-perceived cognitive dysfunction in a prospective, randomized, multicenter study. Psychooncology. 2010;[Epub ahead of print]
  40. Vodermaier A. Breast cancer treatment and cognitive function: the current state of evidence, underlying mechanisms and potential treatments. Womens Health (Lond Engl). 2009;5:503–516
  41. Buckley MR, Lachman VD. Depression in older patients: recognition and treatment. J Am Acad Physicians Assistants. 2007;20:34–41
  42. Konstam V, Moser DK, De Jong MJ. Depression and anxiety in HF. J Card Fail. 2005;11:455–463
  43. Vaccarino V, Kasl SV, Abramson J, et al. Depressive symptoms and risk of functional decline and death in patients with HF. J Am Coll Cardiol. 2001;38:199–205
  44. Pirl WF. Evidence report on the occurrence, assessment, and treatment of depression in cancer patients. J Natl Cancer Inst Monogr. 2004;32:32–39
  45. Bottomley A. Depression in cancer patients: a literature review. Eur J Cancer Care (Engl). 1998;7:181–191
  46. Nelson CJ, Cho C, Berk AR, et al. Are gold standard depression measures appropriate for use in geriatric cancer patients? A systematic evaluation of self-report depression instruments used with geriatric, cancer, and geriatric cancer samples. J Clin Oncol. 2010;28:348–356
  47. Lindenfeld J. Prevalence of anemia and effects on mortality in patients with HF. Am Heart J. 2005;149:391–401
  48. Guigoz Y, Lauque S, Vellas BJ. Identifying the elderly at risk for malnutrition. The Mini Nutritional Assessment. Clin Geriatr Med. 2002;18:737–757
  49. Muss HB, Woolf S, Berry D, et al. Cancer and Leukemia Group B. Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA. 2005;293:1073–1081
  50. Shiffman RN, Shekelle P, Overhage JM, et al. Standardized reporting of clinical practice guidelines: a proposal from the Conference on Guideline Standardization. Ann Intern Med. 2003;139:493–498
  51. Vogeli C, Shields AE, Lee TA, et al. Multiple chronic conditions: prevalence, health consequences, and implications for quality, care management, and costs. J Gen Intern Med. 2007;(Suppl 3):391–395
  52. Corrigan JM, Donaldson MS, Kohn LT, et al. Crossing the quality chasm. A new health system for the 21st century. Washington, DC: Institute of Medicine, National Academy of Sciences, National Academies Press; 2001;
  53. Kaplan SH, Greenfield S, Gandek B, et al. Characteristics of physicians with participatory decision-making styles. Ann Intern Med. 1996;124:497–504
  54. Kaplan SH, Gandek B, Greenfield S, et al. Patient and visit characteristics related to physicians' participatory decision-making style. Results from the Medical Outcomes Study. Med Care. 1995;33:1176–1187

 Statement of Conflict of Interest: see page 177.

PII: S0033-0620(10)00106-4

doi: 10.1016/j.pcad.2010.06.001

Progress in Cardiovascular Diseases
Volume 53, Issue 2 , Pages 173-179 , September 2010

Article Tools

* Image Usage & Resolution